At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Market Closed 12-20 16:00:00 EST
2.23
+0.00
0.00%
盘后2.27
+0.04+1.79%
19:06 EST
High2.28
Low2.07
Vol364.89K
Open2.21
D1 Closing2.23
Amplitude9.42%
Mkt Cap18.41M
Tradable Cap9.10M
Total Shares8.25M
T/O801.39K
T/O Rate8.94%
Tradable Shares4.08M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
HC Wainwright Downgrades CervoMed to Neutral From Buy
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.